BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 31599969)

  • 1. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
    Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
    Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
    Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
    Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation in Patients with Chronic Kidney Disease.
    Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
    Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
    Chen HY; Ou SH; Huang CW; Lee PT; Chou KJ; Lin PC; Su YC
    Clin Drug Investig; 2021 Apr; 41(4):341-351. PubMed ID: 33709339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry.
    Park H; Yu HT; Kim TH; Park J; Park JK; Kang KW; Shim J; Kim JB; Kim J; Choi EK; Park HW; Lee YS; Joung B
    Yonsei Med J; 2023 Jan; 64(1):18-24. PubMed ID: 36579375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
    Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
    Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis.
    Malhotra K; Ishfaq MF; Goyal N; Katsanos AH; Parissis J; Alexandrov AW; Alexandrov AV; Tsivgoulis G
    Neurology; 2019 May; 92(21):e2421-e2431. PubMed ID: 31068485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Significant Tricuspid Regurgitation.
    Yang Y; Kim M; Kim J; Cho MS; Lee S; Song JM; Kim DH
    J Am Heart Assoc; 2024 Feb; 13(3):e032272. PubMed ID: 38293966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
    Fong KY; Chan YH; Yeo C; Lip GYH; Tan VH
    Am J Cardiol; 2023 Oct; 204():366-376. PubMed ID: 37573616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation - Findings From the SAKURA AF Registry.
    Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Circ J; 2018 Sep; 82(10):2500-2509. PubMed ID: 30078823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
    Law SWY; Lau WCY; Wong ICK; Lip GYH; Mok MT; Siu CW; Chan EW
    J Am Coll Cardiol; 2018 Jul; 72(3):271-282. PubMed ID: 30012320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
    Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS
    Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort.
    Sy J; Hsiung JT; Edgett D; Kalantar-Zadeh K; Streja E; Lau WL
    Am J Nephrol; 2021; 52(3):199-208. PubMed ID: 33789276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.